What is the price target for UBX stock?
8 analysts have analysed UBX and the average price target is 3.06 USD. This implies a price increase of 1429.24% is expected in the next year compared to the current price of 0.2001.
UNITY BIOTECHNOLOGY INC (UBX) Forecast, Price Target & Analyst Ratings
NASDAQ:UBX • US91381U2006
Current stock price
0.2001 USD
-0.1 (-33.41%)
At close:
0.1754 USD
-0.02 (-12.34%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for UNITY BIOTECHNOLOGY INC (UBX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Aug 12, 2025
- Period
- Q2 / 2025
- EPS Estimate
- -$0.30
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.06
Upside
+ 1,429.24%
From current price of $0.20 to mean target of $3.06, Based on 8 analyst forecasts
Low
$1.01
Median
$2.04
High
$6.30
Price Target Revisions
1 Month
-7.69%
3 Months
-40.00%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for UBX. The average price target is 3.06 USD. This implies a price increase of 1429.24% is expected in the next year compared to the current price of 0.2001.
The average price target has been revised downward by 40% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
77.50%
UBX was analyzed by 8 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about UBX.
In the previous month the buy percentage consensus was at a similar level.
UBX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-05-27 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-04-23 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-10 | Chardan Capital | Initiate | Buy |
| 2024-08-22 | Rodman & Renshaw | Initiate | Buy |
| 2024-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-16 | Wedbush | Upgrade | Neutral -> Outperform |
| 2023-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-26 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-05-31 | Roth MKM | Initiate | Buy |
| 2023-05-26 | Citigroup | Maintains | Buy -> Buy |
| 2023-05-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-25 | Wedbush | Maintains | Outperform |
| 2023-03-28 | Mizuho | Maintains | Buy |
| 2023-03-28 | Wedbush | Maintains | Outperform |
| 2023-03-28 | Citigroup | Maintains | Buy |
| 2023-03-28 | HC Wainwright & Co. | Reiterate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 12, 2025
- Period
- Q2 / 2025
- EPS Estimate
- -$0.30
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 2.26%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-33.33%
EPS (3 Months)
-27.66%
Next Earnings Summary
UBX is expected to report earnings on 8/12/2025. The consensus EPS estimate for the next earnings is -0.3 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.784M | 236K -95.07% | -100.00% | 39.053M | 8.336M | 20.057M 140.61% | 8.655M -56.85% | 15.919M 83.93% | 23.313M 46.45% | 28.313M 21.45% | 30.214M 6.71% | |||
| EBITDA YoY % growth | -87.852M -0.99% | -53.785M 38.78% | -53.492M 0.54% | -40.225M 30.30% | -27.538M 25.97% | -40.353M -46.21% | -38.843M 3.74% | -43.349M -11.60% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -91.301M -1.84% | -56.665M 37.94% | -55.672M 1.75% | -46.864M 30.91% | -35.306M 26.00% | -34.495M -21.18% | -32.368M 6.16% | -33.425M -3.27% | -12.595M 62.32% | -2.975M 76.38% | 4.862M 263.40% | 12.755M 162.34% | 16.726M 31.13% | |
| Operating Margin | N/A | -1,184.47% | -23,589.83% | N/A | -90.40% | N/A | -388.30% | -166.65% | -145.52% | -18.69% | 20.86% | 45.05% | 55.36% | |
| EPS YoY % growth | -18.10 4.74% | -10.90 39.78% | -7.06 35.23% | -3.28 63.88% | -1.47 40.00% | -1.47 4.15% | -0.95 35.26% | -0.80 15.21% | -0.06 93.10% | 0.13 336.36% | 0.27 107.69% | 0.36 31.48% | 0.41 14.08% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.30 2.26% | -0.30 20.26% | -0.29 41.42% | -0.38 11.45% | -0.38 -26.67% | -0.38 -27.00% |
| Revenue Q2Q % growth | N/A | N/A | N/A | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.465M 21.69% | -3.411M 48.34% | -3.376M 53.66% | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
13.80%
EPS Next 5 Year
15.84%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-19.92%
Revenue Next 5 Year
-16.43%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-7.08%
EBIT Next 5 Year
N/A
UNITY BIOTECHNOLOGY INC / UBX Forecast FAQ
When does UNITY BIOTECHNOLOGY INC (UBX) report earnings?
UNITY BIOTECHNOLOGY INC (UBX) will report earnings on 2025-08-12, after the market close.
What are the consensus estimates for UBX stock next earnings?
The consensus EPS estimate for the next earnings of UNITY BIOTECHNOLOGY INC (UBX) is -0.3 USD and the consensus revenue estimate is 0 USD.
What is the expected long term growth rate for UNITY BIOTECHNOLOGY INC (UBX)?
The expected long term growth rate for UNITY BIOTECHNOLOGY INC (UBX) is -19.92%.